Results 201 to 210 of about 3,289,517 (246)
Minimal Fibrinolysis After Acute Intracerebral Hemorrhage Undercuts the Mechanism of Tranexamic Acid. [PDF]
Silva Pinheiro do Nascimento J +9 more
europepmc +1 more source
Correction to "Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma". [PDF]
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Lancet, 2011
The CRASH-2 trial (July 3, p 23) showed reduced trauma mortality through the simple and cheap inter vention of tranexamic acid, placing it into a growing list of options for managing the acute coagulopathy of trauma. This list includes fresh frozen plasma, cryoprecipitate, platelets, fi brinogen, thrombin, prothrombin complexes, recombinant factor VIIa,
Russell L, Gruen, Biswadev, Mitra
openaire +4 more sources
The CRASH-2 trial (July 3, p 23) showed reduced trauma mortality through the simple and cheap inter vention of tranexamic acid, placing it into a growing list of options for managing the acute coagulopathy of trauma. This list includes fresh frozen plasma, cryoprecipitate, platelets, fi brinogen, thrombin, prothrombin complexes, recombinant factor VIIa,
Russell L, Gruen, Biswadev, Mitra
openaire +4 more sources
A new study has reported on the benefits of tranexamic acid in elective surgery. George Winter explores how it could also be a solution to the inequalities in global health
George F Winter
core +5 more sources
Air Medical Journal, 2022
Tranexamic acid (TXA) has demonstrated a reduction in all-cause mortality in trauma patients with hemorrhage. Administering TXA in the prehospital setting presents unique challenges because the identification of bleeding is based on clinical suspicion without advanced imaging or diagnostic tools.
Joseph DeVitis +12 more
openaire +2 more sources
Tranexamic acid (TXA) has demonstrated a reduction in all-cause mortality in trauma patients with hemorrhage. Administering TXA in the prehospital setting presents unique challenges because the identification of bleeding is based on clinical suspicion without advanced imaging or diagnostic tools.
Joseph DeVitis +12 more
openaire +2 more sources
Annals of Pharmacotherapy, 1996
Tranexamic acid has the potential to be a pharmacologic adjunct for the prophylaxis of hemorrhagic complications occurring in the oncology population. The studies and cases reviewed here suggest that tranexamic acid administration may be a therapeutic option for bleeding prophylaxis in APL where enhanced fibrinolysis accompanies the disease state ...
A H, Seto, D S, Dunlap
openaire +2 more sources
Tranexamic acid has the potential to be a pharmacologic adjunct for the prophylaxis of hemorrhagic complications occurring in the oncology population. The studies and cases reviewed here suggest that tranexamic acid administration may be a therapeutic option for bleeding prophylaxis in APL where enhanced fibrinolysis accompanies the disease state ...
A H, Seto, D S, Dunlap
openaire +2 more sources
Tranexamic Acid for Postpartum Bleeding
Obstetric Anesthesia Digest, 2011The randomized controlled trial of the effect of tranexamic acid (TXA) on blood loss during and after cesarean delivery reported by Movafegh et al. [1] in this issue of IJGO is clinically important for two reasons. First, because hemorrhage is a serious complication of cesarean delivery and their data show that bleeding can be reduced by TXA ...
Ian, Roberts, Katharine, Ker
openaire +2 more sources

